| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – |
| 01 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
– Following productive FDA discussions, Upstream Bio will study 400mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track– |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Upstream Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 9, 2026. As of the close of business on April 13, 2026, the record date for the Annual Meeting, there were 54,419,986 shares o... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – |
| 26 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
Upstream Bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 11 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Top-line Results for the Phase 2 VALIANT Trial in Severe Asthma February 11, 2026 © 2026 Upstream Bio, Inc. Exhibit 99.1 |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12... |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Upstream Bio, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2025. As of April 14, 2025, the record date for the Annual Meeting, there were 53,688,703 shares of the Company’s common s... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – |
| 12 Mar 2025 |
8-K: Results of Operations and Financial Condition
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – |
| 15 Oct 2024 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i... |
Loading...